Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum
(World News USA)

December 11, 2017 Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum New Data Supports Expanded Use of Oncotype DX Breast Recurrence Score® Test for Predicting Treatment Benefit in Neoadjuvant Setting Large Study Demonstrates Excellent Survival without Chemotherapy in Certain Node-positive Patients with Low Recurrence Score Test Results REDWOOD CITY, Calif., Dec. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results of 10 studies that reinforce the unmatched value of the Oncotype DX Breast Recurrence Score® test and Oncotype DX® DCIS ScoreTM test in...